Astellas Pharma Inc. (4503)

2,136.0 +11.0 (+0.52%)
Close JPY Disclaimer

4503 Financial Summary

For the fiscal year ended 31 March 2022, Astellas Pharma Inc revenues increased 4% to Y1.296T. Net income applicable to common stockholders increased 3% to Y124.09B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Total SG&A Expense increase of 9% to Y548.84B (expense), Research and Development Expense increase of 10% to Y246.01B (expense).
TTM
Trailing Twelve Months
MRQ
Most Recent Quarter
4503
Gross margin TTM 80.1%
Operating margin TTM 17.5%
Net Profit margin TTM 10.59%
Return on Investment TTM 12.98%
Total Revenue
Net Income
Title
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Total Revenue 380,394 340,627
Gross Profit 317,613 271,268
Operating Income 85,311 79,202
Net Income 71,623 24,812 60,886
Clear All
0Selected
Please try another search
4503
Quick Ratio MRQ 1.11
Current Ratio MRQ 1.39
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 0.3%
Total Assets
Total Liabilities
Title
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Total Assets 2,583,661 2,332,395 2,356,245
Total Liabilities 934,143 872,087 889,954
Total Equity 1,649,518 1,460,308 1,466,291
Clear All
0Selected
Please try another search
4503
Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow 11.95%
Cash
Net Change in Cash
Title
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Cash From Operating Activities 91,025 208,859
Cash From Investing Activities -15,516 -47,586
Cash From Financing Activities -34,829 -141,264
Net Change in Cash 48,060 24,085
Clear All
0Selected
Please try another search

* In Millions of JPY (except for per share items)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles